flare up of atopic dermatitis/this flare up did not happen until after caller got the first booster of the Pfizer COVID-19 vaccine; flare up of atopic dermatitis/this flare up did not happen until after caller got the first booster of the Pfizer COVID-19 vaccine; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 80-year-old male patient received BNT162b2 (BNT162B2), on 28Sep2021 as dose 3 (booster), single (Lot number: 301308A) at the age of 80 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Chronic obstructive pulmonary disease" (unspecified if ongoing); "Gastrooesophageal reflux disease" (unspecified if ongoing); "Cholesterol" (unspecified if ongoing); "Restless legs" (unspecified if ongoing); "caller is a previous smoker" (unspecified if ongoing); "Joint pain" (unspecified if ongoing); "Hiatal hernia" (unspecified if ongoing); "Age-related macular degeneration" (unspecified if ongoing); "Dry cough" (unspecified if ongoing); "Shortness of breath" (unspecified if ongoing); "Covid-19", start date: 2020 (unspecified if ongoing); "Asthma" (unspecified if ongoing); "Enlarged prostate" (unspecified if ongoing); "Knee replacement" (unspecified if ongoing). Concomitant medication(s) included: ZYRTEC [CETIRIZINE HYDROCHLORIDE] taken for hypersensitivity; SINGULAIR taken for asthma; UROXATRAL taken for prostatomegaly. Vaccination history included: BNT162b2 (Dose: 2, Lot number: EN6198; Expiration date: Unknown), administration date: 26Feb2021, when the patient was 80-year-old, for COVID-19 Immunization; BNT162b2 (Dose: 1, Lot number: EL9262; Expiration date: Unknown), administration date: 02Feb2021, when the patient was 80-year-old, for COVID-19 Immunization. The following information was reported: DERMATITIS ATOPIC (non-serious), DERMATITIS ATOPIC (non-serious) all with onset 2021, outcome "unknown" and all described as "flare up of atopic dermatitis/this flare up did not happen until after caller got the first booster of the Pfizer COVID-19 vaccine". Therapeutic measures were taken as a result of dermatitis atopic, dermatitis atopic.  Additional information: The expiration date for first BOOSTER dose was unknown. The patient confirms all 4 doses were the Pfizer COVID-19 vaccine. Patient received 4th dose (Second BOOSTER) on 14Apr2022, last week (Lot number: FJ6369; Expiration date: unknown). Patient was taking medications for GERD and COPD and cholesterol medications at maximum strength and also has restless legs, so caller has several maintenance medications that caller takes. Patient states the COPD, GERD and restless legs began prior to starting these medications. Patient had no lifestyle changes, He is a previous smoker, has the joint pain, and has a hiatal hernia; states this was prior to the medications. Patient had double knee replacement and had joint pain from that; states this was also prior to taking the medication. Provides 2 other medications that are maintenance medications. Takes Sinclair which is a tablet for asthma and Uroxatral for enlarged prostate. States asthma and enlarged prostate were prior to all the events he was calling about today (the day of reporting). Patient has a chronic dry cough which he thinks is related to the COPD and shortness of breath. He is also under treatment for AMD, macular degeneration. He confirms these events were prior to starting these medications. Also takes Zyrtec to control itching. The Zyrtec is working very well for him right now, 10mg and takes once a day but can take twice a day in 24 hours as needed and depends on how active he is. Patient has a more than acceptable amount of stress in his family now which could be a trigger to the flare up of atopic dermatitis, but caller says this flare up did not happen until he got the first booster of the Pfizer COVID-19 vaccine, he never had atopic dermatitis before that. Atopic dermatitis started after the holidays, between Oct2021 and Dec2021, was not sure because he was traveling. He had to make an appointment with GP (general practitioner) for the Kenalog shot (NDC number, lot number, expiration date: unknown). After the holidays he began another treatment with GP (general practitioner) which was a Kenalog shot for itching. That lasted a short period of time and then he went on Prednisone (NDC number, lot number, expiration date: unknown) to control the itching for another couple of weeks. Then he made an appointment in the end of Jan2022. That's when prescribed with Dupixent. Currently he was taking Dupixent (NDC number of Dupixent: 0024591502; Lot number: 1F099A Expiry Date: 31Dec2023; it is a pen, 2ml, 300mg. generic name dupilumab) for atopic dermatitis but says Dupixent doesn't seem to be working as well for the atopic dermatitis. After about 3 months of treatment of Dupixent his dermatologist said the medication isn't working as well as it should. The patient think would be the end of Jan2022, has had 4 shots of the Dupixent, the prescription was written on 31Jan2022.Patient was being prescribed Cibinqo, 100mg tablets 30 for 30. Patient has an appointment on Thursday to see if Cibinqo is a good fit for him. He is not on Cibinqo currently and hence NDC number, lot number and expiration date of Cibinqo not Provided. Patient was concerned about side effects of the Cibinqo medication and is particularly concerned about the chance for stroke and side effects to the circulation system because he has COPD and GERD.